StageZero Life Sciences ARISTOTLE Multi-Cancer Blood Test Now Available In Greater Toronto Area

StageZero Life Sciences, Ltd. ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced that people throughout the Greater Toronto Area can now access the company's multi-cancer blood test ARISTOTLE. Built on StageZero's proprietary mRNA technology, ARISTOTLE is a next-generation test which simultaneously screens for multiple cancers from a single sample of blood.

Cancer is the leading cause of death in Canada.¹ In 2021, an estimated 229,000 Canadians will be diagnosed with cancer.1 Treatment is most likely to be effective when cancer is diagnosed at an early stage; however, some of the most common cancers are not diagnosed until symptoms arise and the tumor has progressed to an advanced stage.1 For example, currently about 50% of colorectal cancers are diagnosed at stage III or IV.¹

"Far too often, cancer is diagnosed and treated at a late stage, which can dramatically decrease survival rates and affect patients' quality of life," said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. "This is more of an issue now, with the COVID-19 pandemic having significantly reduced patient/physician interactions. We are seeing a wave of late-stage diagnoses" he continued. "Use of a blood test that looks for the most common forms of treatable cancers can help reduce the risk of developing advanced-stage cancer through early detection. We believe that providing an opportunity to find cancer early will facilitate more favorable outcomes."

ARISTOTLE must be prescribed by a physician and is available through AVRT, the Company's comprehensive telehealth program which uses advanced diagnostics and physician supervision to help patients detect cancer in the earliest stages. Through AVRT, patients who have a molecular signature for cancer detected via ARISTOTLE are paired with a dedicated case manager, oncologist, and/or other healthcare professionals to guide them on next steps.

Collaborations with clinics in the Greater Toronto Area will facilitate specimen collection and are part of StageZero's physical hub-and-spoke model which is being deployed as part of the Company's long-term Global Growth Strategy.

ARISTOTLE is the first-ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The ARISTOTLE test works by interrogating mRNA from a sample of whole blood and detecting gene expression profiles indicative of specific cancers. ARISTOTLE screens for the molecular signatures associated with multiple, individual cancers, including breast, ovarian, endometrial, colorectal, liver, stomach, prostate, and others.

For more information, visit https://www.stagezerolifesciences.com/aristotle-test.html.

Reference

1. https://cdn.cancer.ca/-/media/files/research/cancer-statistics/2021-statistics/2021-pdf-en-final.pdf